• Clinical evaluation of the efficacy of new drugs and new treatment approaches for gliomas and meningiomas (Jordi Bruna, Miguel Gil, Ana Lucas, Miquel Macià, Carles Majós)
    • Chemotherapy-induced peripheral neuropathies (Jordi Bruna, Roser Velasco)
    • Cancer and cognition (Marta Simó)
    • Leptomeningeal metastases (Jordi Bruna, Miguel Gil)
    • Survival prognostic factors involved in central nervous system tumours (Noemí Vidal, Jordi Bruna, Carles Majós)
    • Prevention and personalised treatment of brain metastases: development of new therapies based on the prevention and prognosis of biomarkers (Miguel Gil, Noemí Vidal, Gerard Plans, Ana Lucas)

Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity

Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Alberti P, Bruna J, Argyriou AA, Briani C, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Faber CG, Lalisang RI, Brandsma D, Koeppen S, Kerrigan S, Schenone A, Grisold W, Mazzeo A, Padua L, Dorsey SG, Penas-Prado M, Valsecchi MG, CI-PeriNomS Group

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. (ISSN/ISBN: 10859489).

2019

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age

Castet F, Alanya E, Vidal N, Izquierdo C, Mesia C, Ducray F, Gil-Gil M, Bruna J

2019

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer

Morán T., Felip E., Bosch-Barrera J., de Aguirre I., Ramirez J., Mesia C., Carcereny E., Roa D., Sais E., García Y., Blanco R., Sanchez S., Villacorta C., Queralt C., Velarde J., Rosell R.

ONCOTARGET. (ISSN/ISBN: 19492553). 9(43): 27074-27086

2018

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer (Oncotarget (2018) 9 (27074-27086) DOI: 10.18632/oncotarget.25478)

Morán T, Felip E, Bosch-Barrera J, De Aguirre I, Ramirez J, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta C, Queralt C, Velarde J, Rosell R

2018

Involvement of both caspase-8 and Noxa-activated pathways in endoplasmic reticulum stress-induced apoptosis in triple-negative breast tumor cells.

Cano-González A; Mauro-Lizcano M; Iglesias-Serret D; Gil J; López-Rivas A

CELL DEATH DIS (ISSN/ISBN: 20414889). 9 (2) : 134-134

2018

Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics

Izquierdo C., Alentorn A., Idbaih A., Simó M., Kaloshi G., Ricard D., Barritault M., Meyronet D., Bruna J., Honnorat J., Delattre J., Ducray F.

JOURNAL OF NEURO-ONCOLOGY (ISSN/ISBN: 0167594X). 136 (3) : 533-539

2018

Sphingolipid metabolism products: potential new players in the pathogenesis of bortezomib-induced neuropathic pain

Ale, Albert; Argyriou, Andreas A.; Bruna, Jordi;

ANNALS OF TRANSLATIONAL MEDICINE. (ISSN/ISBN: 2305-5839). 6(S78):

2018

Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations

Izquierdo C, Barritault M, Poncet D, Cartalat S, Joubert B, Bruna J, Jouanneau E, Guyotat J, Vasiljevic A, Fenouil T, Berthezène Y, Honnorat J, Meyronet D, Ducray F

NEUROSURGERY. (ISSN/ISBN: 0148396X).

2018

Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy.

Bruna J, Velasco R

NEURAL REGENERATION RESEARCH (ISSN/ISBN: 16735374). 13 (5) : 775-778

2018

Inconclusive evidence to support the use of minimally-invasive radiofrequency denervation against chronic low back pain

Argyriou, Andreas A.; Anastopoulou, Garifallia G.; Bruna, Jordi;

ANNALS OF TRANSLATIONAL MEDICINE (ISSN/ISBN: 2305-5839). 6 (7) : ARTN 127

2018

See full list

CONTRATOS PARA LA INTENSIFICACION DE LA ACTIVIDAD INVESTIGADORA EN EL SNS

Bruna Escuer, Jordi (Investigador principal (IP))

Ref.: INT16/00219

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2017-01-01 - 2017-04-07

Toxicitat cognitiva induïda per la quimioteràpia en pacients amb càncer de pulmó

Simo Parra, Marta (Participante)

CONTRATOS JUAN RODES

Simo Parra, Marta (Investigador principal (IP))

Ref.: JR15/00027

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2016-01-04 - 2019-01-03

Estudio exploratorio sobre la etiopatogenia, biomarcadores de riesgo y mecanismos implicados en la regeneración de la neuropatía inducida por platinos

Bruna Escuer, Jordi (Investigador principal (IP))

Ref.: PI15/01303

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2016-01-01 - 2018-12-31

An observational retrosepctive cohort study to evaluate the progression-free survival and overall survival at patients who participated in the SIGM-202 clinical trial

Simo Parra, Marta (Participante)

Entitat finançadora:
  • LABORATORIOS DR. ESTEVE, S.A.

Posible utilidad de la resonancia magnética preradioterapia precos (PRMR) para el seguimiento de los gliomas de alto grado

MAJOS TORRO, CARLOS (Investigador principal (IP))

Ref.: PR309/12

Entitat finançadora:
  • GEINO

2013-04-01 - 2016-03-31

Neurocognitive function sub-study of BO21990: A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma

Simo Parra, Marta (Investigador/a)

Entitat finançadora:
  • ROCHE FARMA, S.A.

Ensayo prospectivo multicéntrico de NovoTTF-100A en combinación con temozolomida comparado con temozolomida en monoterapia en pacientes con GBM de reciente diagnóstico

Simo Parra, Marta (Investigador/a)

Entitat finançadora:
  • NOVOCURE LTD

A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer. NCT01657799

Simo Parra, Marta (Investigador/a)

Entitat finançadora:
  • ABBOTT CIENTÍFICA, S.A.

CONTRATOS POST FSE RIO HORTEGA

Simo Parra, Marta (Investigador principal (IP))

Ref.: CM11/00256

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2012-01-24 - 2014-01-23

See full list

METHOD FOR DETERMINING THE RISK OF DEVELOPING BRAIN METASTASIS, AND A KIT TO CARRY OUT SAID METHOD

Sanz Pamplona, Rebeca (Inventores-as/autores-as/obtentores-as); SIERRA JIMENEZ, Angels (Inventores-as/autores-as/obtentores-as); OLIVA MIGUEL, Baldomero (Inventores-as/autores-as/obtentores-as); Moreno Aguado, Victor Raul (Inventores-as/autores-as/obtentores-as); Gil Gil, Juan Miguel (Inventores-as/autores-as/obtentores-as)

See full list

  • Identification of markers of clinical and neurophysiological predictive risk for developing oxaliplatin-induced neuropathy.
  • New demonstrations on the efficacy of the new sigma-1 receptor antagonist in preventing acute oxaliplatin-induced neuropathy in a randomised, phase 2 study.
  • Documentation of longitudinal brain changes associated with prophylactic cranial irradiation and chemotherapy in patients with small-cell lung cancer.
  • Identification of a common feature in glioblastomas: intrinsic deficiency of the DFF40/CAD endonuclease which affects DNA hydrolysis during caspase-dependent cell death.